NCT02139397View on ClinicalTrials.gov

Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 6, 2014

Primary Completion Date

January 19, 2024

Study Completion Date

January 19, 2024

Conditions
Neuroblastoma Recurrent
Interventions
DRUG

DFMO

DRUG

Bortezomib

Trial Locations (6)

29425

Medical University of South Carolina, Charleston

32806

Arnold Palmer Hospital for Children- MD Anderson, Orlando

49503

Helen DeVos Children's Hospital, Grand Rapids

64108

Children's Mercy Hospitals and Clinics, Kansas City

72202

Arkansas Children's Hospital, Little Rock

06106

Connecticut Children's Hospital, Hartford

Sponsors

Collaborators (1)

K C Pharmaceuticals Inc.
All Listed Sponsors
collaborator

Beat NB Cancer Foundation

OTHER

collaborator

Because of Ezra

OTHER

collaborator

K C Pharmaceuticals Inc.

INDUSTRY

lead

Giselle Sholler

OTHER